LYEL

13.8001.62%
SJ

Stephen J. Hill

Chief Operating Officer

Mr. Stephen J. Hill, M.B.A., is Director of Sonoma Biotherapeutics, Inc. from July 2026. He serves as Chief Operating Officer of Lyell Immunopharma, Inc. since November 01, 2021 and served as Chief Technical Operations Officer of Lyell Immunopharma, Inc since June 2019 until November 01, 2021. He joined Lyell in June 2019. Mr. Hill was most recently Senior Vice-President, Head of Global Biologics Operations at AstraZeneca, from June 2018 to June 2019. He was responsible for end-to-end supply of the commercial and late-stage clinical portfolio for Biologics that includes oversight of six manufacturing sites across the US and Europe and five commercial products. Under his leadership, Biologics Operations played a pivotal role in the company’s return to growth strategy through successful on-time, in-full delivery of more than fifty market launches for Imfinzi, Fasenra and Lumoxiti. He was focused on driving network performance, reliability and supply while developing a robust management system and high performing, inclusive organization. As Vice President Operations, Site Head at the AstraZeneca Frederick Manufacturing Center from March 2016 to June 2018. Mr. Hill was responsible for the largest biologics manufacturing facility within the company’s global network. The site consists of a licensed, large-scale cell culture production facility and recently commissioned small-scale clinical and commercial facility. Prior to AstraZeneca Mr. Hill served as Vice President Bulk Manufacturing at Amgen’s Puerto Rico facility and as Executive Director leading commercial formulation and filling and commercial drug substance operations. In these roles he drove Lean Transformation resulting in significant operational efficiencies and successful new product introductions. From December 2012 through February 2016, Mr. Hill served in multiple positions at Amgen Inc., including. Mr. Hill also served prior roles as Executive Director, Manufacturing Technologies leading manufacturing global networks and as Executive Director, Plant Manager leading clinical drug substance operations. In his corporate role he led manufacturing of the future, operations strategy, high reliability performance and manufacturing global network initiatives. In his plant Manager role he was an effective change agent driving productivity improvement while increasing output to deliver multiple pipeline new product introductions annually. Mr. Hill joined Amgen from ICOS Corporation where he executed GMP clinical plant start-up and led manufacturing, ultimately transitioning the operation into a contract manufacturing business. Mr. Hill started his career at Immunex Corporation as an operator manufacturing Enbrel. Hill holds a master’s in business administration (MBA) and Bachelor’s in Microbiology (BS) and Political Science (BA) from the University of Washington.

Positions